Discover an SMA treatment that’s delivered directly to the central nervous system to target an underlying cause of motor neuron loss in SMA1,2

How does SPINRAZA work?

SPINRAZA is a modified antisense oligonucleotide designed to target an underlying cause of motor neuron loss
in SMA1  

Explore the MOA
Data and Safety Profile

SPINRAZA has been studied in the longest SMA clinical trial program to date3

Discover the Data Safety Profile
Dedicated Patient Support

If patients or caregivers are experiencing nonmedical barriers to accessing treatment–such as the cost of SPINRAZA–Biogen may be able to help

Learn More

Extensive real-world experience across a broad range of ages*

have been treated with
SPINRAZA worldwide1*

there’s someone from almost every
age group who has taken SPINRAZA1,3

have been treated with
SPINRAZA worldwide3,*

*Based on commercial patients, early access patients, and clinical trial participants through May 2022.
Clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose but did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
Based on commercial patients in the US (including Puerto Rico) through May 2022.

a later-onset adult patient with spinal muscular atrophy on SPINRAZA

“Around age 32, I had moved across the country and started working with a new doctor. I was feeling weaker but learning to accept it. My doctor mentioned a treatment to me
called SPINRAZA.”